Adicet Bio, Inc.
ACET
$-0.01
Change (1 day)
$3.77
Year High
$1.05
Year Low
Categories
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Adicet Bio, Inc. (ACET) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -138,787,000 | 37.12 M | 207.3 M | 162.27 M | |
| 2022 | 435 K | -236,633,000 | 38.35 M | 330.69 M | 261.04 M |
| 2021 | 214 K | -256,600,000 | 35.81 M | 338.94 M | 282.44 M |
| 2020 | 2.73 M | -62,691,000 | 44.01 M | 153.84 M | 94.61 M |
| 2019 | 935 K | 103.48 M | 141.95 M | 81.59 M | 64.19 M |